Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial
A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial ...
Oct 19, 2023
0
84